Chinese manufacturing facility
Thermo Fisher Scientific has announced plans for a new manufacturing facility in China within the Suzhou Science and Technology Town as part of the company's expansion in the region.
Thermo Fisher Scientific has announced plans for a new manufacturing facility in China within the Suzhou Science and Technology Town as part of the company's expansion in the region. The new facility, scheduled for completion in early 2012, will develop and manufacture laboratory instruments, equipment and consumables for China's growing life sciences markets.
"China is undergoing tremendous changes that impact its population, from healthcare to the environment to food safety, creating new opportunities for investment and growth," said Marc N. Casper, company president and CEO. "China continues to grow significantly and is now our third largest country in terms of revenue. By bringing Suzhou online to complement our existing facilities, we continue to increase our depth of capabilities and strengthen our competitive advantage in the region."
The company recently reported that its revenues in China grew by more than 14 per cent in 2010 year to year.
For more information visit www.thermofisher.com
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.
